Ferring acquires rights to food supplement from CD Investments

Ferring has agreed a deal to gain the rights to the food supplement product VSL#3 from CD Investments (CDI).

Under the exclusive deal, Ferring will extend its rights to market the supplement in the UK, Italy and Canada, allowing it to broaden its gastroenterology portfolio and build upon its regional pharmabiotic strategy.

VSL#3 contains 450 billion live bacteria in eight different strains per sachet, colonising the gut with a special formulation of beneficial organisms that have been selected, cultivated and mixed carefully in the optimal proportions.

Studies have shown that probiotic bacteria can help to modulate mucosal and systemic immune activity and epithelial function, leading to a positive impact on gut health.

Gilles Pluntz, senior vice-president for Europe and Canada at Ferring Pharmaceuticals, said: "This agreement complements our innovative research in the area of the human microbiome, and reflects Ferring's commitment to enhancing the quality of life of patients with a broad range of bowel conditions."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.